{"id":205,"date":"2017-03-27T14:06:05","date_gmt":"2017-03-27T13:06:05","guid":{"rendered":"http:\/\/inmunologia.webs.uvigo.es\/?page_id=205"},"modified":"2018-06-13T17:47:12","modified_gmt":"2018-06-13T16:47:12","slug":"nanomedicine","status":"publish","type":"page","link":"https:\/\/inmunologia.webs9.uvigo.es\/?page_id=205","title":{"rendered":"Nanomedicine"},"content":{"rendered":"

In our group we have worked for years on the application of the Nanotechnology advances to the Medicine field.<\/p>\n

Nanoparticle-based technology has proven to be an extraordinary tool to develop new drug delivery nanosystems<\/strong> and antigen delivery systems<\/strong>. These systems can be used for the development of nanovaccines<\/strong> and we have worked on new prototypes for the prevention of infectious diseases but also as therapeutics for autoimmune diseases.<\/p>\n

To be considered as a candidate for biomedicine purposes, the characterization of the interaction of the nanosystems with a biological environment is indispensable. Related to this, our group has worked hard in the nanotoxicology<\/strong> field, performing several in vitro and in vivo studies to ascertain the possible cytototoxic effect of different nanosystems, prior to its administration in vivo.<\/p>\n

We have also applied nanotechnology resources for the development of biosensors with a potential application in clinics to detect serum proteins such as PCR, alpha-phetoprotein, etc. (Biosensor line research).<\/p>\n

Our interest is the potential\u00a0application of nanostructures in the biomedical field:<\/p>\n